Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merck KGaA - SIC # 3827 - OPTICAL INSTRUMENTS AND LENSES
Ticker
Exchange
SIC #
Website
Latest Ticker
MKKGY
Over the counter
3827
www.emdgroup.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merck KGaA
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer
- May 21st, 2026 9:30 am
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
- May 21st, 2026 6:00 am
Some Investors May Be Willing To Look Past Merck KGaA's (ETR:MRK) Soft Earnings
- May 20th, 2026 10:38 pm
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
- May 18th, 2026 7:40 am
BAVENCIO Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
- May 15th, 2026 2:12 am
Merck KGaA (MKGAF) Q1 2026 Earnings Call Highlights: Strong Start with Life Science and ...
- May 13th, 2026 5:03 pm
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
- May 13th, 2026 5:10 am
Merck KGaA Broadens Growth Story With Gene Therapy And Hybrid Drugs
- May 12th, 2026 9:13 am
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
- May 11th, 2026 4:05 pm
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
- May 7th, 2026 9:30 am
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
- May 7th, 2026 6:50 am
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
- May 7th, 2026 6:00 am
How The Merck KGaA (XTRA:MRK) Investment Story Is Shifting As Analysts Reset Expectations
- May 2nd, 2026 2:10 am
Merck KGaA AGM: CEO Garijo’s final address, stable €2.20 dividend, Beckmann to take over May 1
- May 1st, 2026 9:28 am
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
- Apr 30th, 2026 6:05 am
[Latest] Global Cell Culture Media Bags Market Size/Share Worth USD 2.28 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- Apr 28th, 2026 10:30 pm
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
- Apr 28th, 2026 6:00 am
Remepy Announces Collaboration with Merck KGaA, Darmstadt Germany to Advance Hybrid Drugs Across Therapeutic Areas
- Apr 28th, 2026 5:00 am
Here's What We Like About Merck KGaA's (ETR:MRK) Upcoming Dividend
- Apr 22nd, 2026 10:00 pm
$10+ Bn Microbiology Testing Market Analysis by Product, Technology, End User - Global Forecast to 2031
- Apr 22nd, 2026 2:24 am
Scroll